June 8, 2023 10:49 AM EDT

FDA accepts another sBLA for Merck's Keytruda, following Imfinzi in biliary tract cancer

Merck announced Thursday morning that the FDA has accepted an sBLA for its sales kingpin and anti-PD-1 therapy Keytruda, setting a …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA ac­cepts an­oth­er sBLA for Mer­ck­'s Keytru­da, fol­low­ing Imfinzi in bil­iary tract can­cer